VANCOUVER, BRITISH COLUMBIA--(Marketwire - Nov. 18, 2008) - Allon Therapeutics Inc. (TSX:NPC) announced today that it has been issued a United States patent covering the use of its neuroprotective drugs as potential treatments for peripheral neuropathy, a group of debilitating and painful conditions suffered by millions of people and resulting from nerve damage for which there is currently no effective treatment available. Among the major causes of neuropathy are diabetes and cancer chemotherapy.
